[go: up one dir, main page]

GB857194A - Therapeutic agents comprising ion-exchange resins - Google Patents

Therapeutic agents comprising ion-exchange resins

Info

Publication number
GB857194A
GB857194A GB21336/57A GB2133657A GB857194A GB 857194 A GB857194 A GB 857194A GB 21336/57 A GB21336/57 A GB 21336/57A GB 2133657 A GB2133657 A GB 2133657A GB 857194 A GB857194 A GB 857194A
Authority
GB
United Kingdom
Prior art keywords
acid
resin
basic
combined
acidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB21336/57A
Inventor
Herbert Timmington
Wilfred Herbert Linnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Products Ltd
Original Assignee
Clinical Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Products Ltd filed Critical Clinical Products Ltd
Priority to GB21336/57A priority Critical patent/GB857194A/en
Publication of GB857194A publication Critical patent/GB857194A/en
Priority to MY196340A priority patent/MY6300040A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of drugs combined with ionexchange resins are prepared wherein two or more drugs all of which are either acidic or basic in nature are combined with a single quantity of an appropriate (i.e. oppositely charged) cationic or anionic ion-exchange resin which is formed from either a co-polymer of styrene containing acidic or basic groups, or from a polymerized methacrylic acid cross-linked with divinyl benzene and containing carboxylic acid groups. Specified resins are; strong cationic exchange resins containing sulphonic acid groups, weak cationic exchange resins containing carboxyl groups strong anionic exchange resins containing quaternary ammonium groups, weak anionic exchange resins containing primary amino groups. Examples of "basic" drugs which may be used are; basic alkaloids, e.g. morphine, ephedrine, atropine; basic alkaloids containing acidic groups e.g. trigonelline, arecaidine, ecgonine; antihistamines; basic vitamins e.g. aneurine, pyridoxine, riboflavine; derivatives of phenylalkyl amines. Examples of "acidic" drugs are; barbituric acid derivatives, aspirin, valerianic acid, acidic vitamins e.g. ascorbic acid, nicotinic acid, pantothenic acid, folic acid. In specific examples, the preparation is described of; (i) a cross-linked polystyrene resin e.g. Zeokarb 225H or Amberlite IR-120 combined with both hyoscine and hyoscyamine; (ii) a resin of the same type combined with both hyoscyamine and ephedrine; (iii) an anionic exchange resin e.g. De Acidite FF combined with both amylobarbitone and pheno-barbitone. The compounds are prepared by allowing the resin to react with an aqueous solution of one drug in a soluble form e.g. as an acidic addition or alkali metal salt, until a sufficient amount has combined with the resin and repeating the process with an aqueous solution of the second drug and the resin/drug compound obtained from the first step. Specification 857,193 is referred to.ALSO:Orally administrable therapeutic preparations comprise two or more drugs all of which are either of basic or acidic nature combined with a single quantity of an appropriate (i.e. oppositely charged) cationic or anionic ion-exchange resin which is formed from either a co-polymer of styrene containing acidic or basic groups, or a polymerised methacrylic acid cross-linked with divinyl benzene and containing carboxylic acid groups. Specified resins are; (a) strong cationic exchange resins containing the sulphonic acid groups e.g. "Zeokarb" 225, "Amberlite" IR-120, Dowex 50 ("Zeokarb" and "Amberlite" are Registered Trade Marks); (b) weak cationic exchange resins containing the carboxyl group e.g. Zeokarb 226, Amberlite IRC-50; (c) strong anoinic exchange resins containing quaternary ammonium groups e.g. De Acidite FF ("De Acidite" is a Registered Trade Mark), Amberlite IRA-400, Dowex 1 and 2; (d) weak anionic exchange resins containing the primary amino group e.g. DeAcidite E, Amberlite IR-45. Examples of "basic" drugs which may be used are; basic alkaloides e.g. morphine, ephedrine, atropine; basic alhaloids containing acidic groups e.g. trigonelline, arecaidine, ecgonine; antihistamines; basic vitamins e.g. aneurine, pyridexine, riboflavine; derivatives of phenyl-alkyl amines. Examples of "acidic" drugs are; barbituric acid derivatives, aspirin, valerianic acid, acidic vitamins e.g. ascorbic acid, nicotinic acid, pantothenic acid, folic acid. Specific examples of "multiple resin/drug compounds" are hyoscyamine and Hyoseine combined with a sulphuric acid crosslinked polystyrene resin (Zeokarb 225H and Amberlite IR-120); hyoseyamine and ephedrine combined with the same resin type; amylobarbitone and pheno barbitone combined with an anionic exchange resin e.g. De Acidite FF. The two drugs may be combined with the resin in the desired proportions and, if desired, the combination may be "diluted" by the addition of further pure ion-exchange resin. The resin/drug compounds may be incorporated into various pharmaceutical forms e.g. tablets, powders, capsules, granules, suspensions in water or oil. Specification 857,193 is referred to.
GB21336/57A 1957-07-05 1957-07-05 Therapeutic agents comprising ion-exchange resins Expired GB857194A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB21336/57A GB857194A (en) 1957-07-05 1957-07-05 Therapeutic agents comprising ion-exchange resins
MY196340A MY6300040A (en) 1957-07-05 1963-12-31 Therapeutic agents comprising ion-exchange resins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB21336/57A GB857194A (en) 1957-07-05 1957-07-05 Therapeutic agents comprising ion-exchange resins

Publications (1)

Publication Number Publication Date
GB857194A true GB857194A (en) 1960-12-29

Family

ID=10161155

Family Applications (1)

Application Number Title Priority Date Filing Date
GB21336/57A Expired GB857194A (en) 1957-07-05 1957-07-05 Therapeutic agents comprising ion-exchange resins

Country Status (2)

Country Link
GB (1) GB857194A (en)
MY (1) MY6300040A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012804A1 (en) * 1978-12-21 1980-07-09 ALFA FARMACEUTICI S.p.A. Salts of a non toxic, activated anion exchange resin capable of establishing a stable binding with bile acids and 2-(4'-(p-chlorobenzoyl)-phenoxy)-2-(methyl)-propionic acid and pharmaceutical compositions comprising these salts
EP0154895A2 (en) * 1984-03-09 1985-09-18 ISTITUTO LUSO FARMACO D'ITALIA S.p.A. New sulfonic resins having a therapeutical activity, preparation thereof and pharmaceutical compositions containing them
EP0244704A2 (en) * 1986-04-28 1987-11-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Photoelectrographic elements and imaging method
EP0845481A2 (en) * 1993-02-17 1998-06-03 Btg International Limited Polymers containing guanidino groups for use in therapy
WO2000072959A1 (en) * 1999-05-26 2000-12-07 Eli Lilly And Company Resins with immobilized ascorbic acid
US6193962B1 (en) * 1997-07-24 2001-02-27 Astrazeneca Uk Limited Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin
WO2003024444A1 (en) * 2001-09-18 2003-03-27 Grünenthal GmbH Combination of selected opioids with muscarine antagonists for treating urinary incontinence
CN108610339A (en) * 2018-04-19 2018-10-02 安徽德信佳生物医药有限公司 The technique of extraction separation hyoscine in a kind of datura flower from low content

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012804A1 (en) * 1978-12-21 1980-07-09 ALFA FARMACEUTICI S.p.A. Salts of a non toxic, activated anion exchange resin capable of establishing a stable binding with bile acids and 2-(4'-(p-chlorobenzoyl)-phenoxy)-2-(methyl)-propionic acid and pharmaceutical compositions comprising these salts
US4340585A (en) 1978-12-21 1982-07-20 Alfa Farmaceutici, S.P.A. Salified anionic resin for cholesterol and lipid lowering
EP0154895A2 (en) * 1984-03-09 1985-09-18 ISTITUTO LUSO FARMACO D'ITALIA S.p.A. New sulfonic resins having a therapeutical activity, preparation thereof and pharmaceutical compositions containing them
EP0154895A3 (en) * 1984-03-09 1987-05-06 Istituto Lusofarmaco D'italia S.P.A. New sulfonic resins having a therapeutical activity, preparation thereof and pharmaceutical compositions containing them
EP0244704A2 (en) * 1986-04-28 1987-11-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Photoelectrographic elements and imaging method
EP0244704A3 (en) * 1986-04-28 1989-08-30 EASTMAN KODAK COMPANY (a New Jersey corporation) Photoelectrographic elements and imaging method
EP0845481A3 (en) * 1993-02-17 2001-01-03 Btg International Limited Polymers containing guanidino groups for use in therapy
EP0845481A2 (en) * 1993-02-17 1998-06-03 Btg International Limited Polymers containing guanidino groups for use in therapy
US6193962B1 (en) * 1997-07-24 2001-02-27 Astrazeneca Uk Limited Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin
WO2000072959A1 (en) * 1999-05-26 2000-12-07 Eli Lilly And Company Resins with immobilized ascorbic acid
WO2003024444A1 (en) * 2001-09-18 2003-03-27 Grünenthal GmbH Combination of selected opioids with muscarine antagonists for treating urinary incontinence
AU2002342707B2 (en) * 2001-09-18 2006-10-12 Gruenenthal Gmbh Combination of selected opioids with muscarine antagonists for treating urinary incontinence
CN100384413C (en) * 2001-09-18 2008-04-30 格吕伦塔尔有限公司 Combinations of selected opioids and muscarine antagonists for the treatment of urinary incontinence
KR100891438B1 (en) * 2001-09-18 2009-04-03 그뤼넨탈 게엠베하 Combination of muscarinic antagonists with selected opioids and pharmaceutical compositions for treating incontinence
US8946290B2 (en) 2001-09-18 2015-02-03 Gruenenthal Gmbh Combination of selected opioids with muscarine antagonists for treating urinary incontinence
CN108610339A (en) * 2018-04-19 2018-10-02 安徽德信佳生物医药有限公司 The technique of extraction separation hyoscine in a kind of datura flower from low content

Also Published As

Publication number Publication date
MY6300040A (en) 1963-12-31

Similar Documents

Publication Publication Date Title
DE68912882T2 (en) Active ingredient resin complexes with delayed release.
DK175154B1 (en) Process for preparing a pharmaceutical ion exchange resin composition
US3773920A (en) Sustained release medicinal composition
GB857194A (en) Therapeutic agents comprising ion-exchange resins
KR890016968A (en) Pharmaceutical adsorbate
KR840007562A (en) Process for preparing resin acid salt of substituted carboxylic acid
GB929391A (en) Therapeutic compositions comprising polymeric amines
IE43536L (en) Ion-exchange separation of proteins
GB1378348A (en) Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2966564D1 (en) Therapeutic compositions with enhanced bioavailability and process for their preparation
KR900011451A (en) New Pharmaceutical Formulations
ES357071A1 (en) Pharmaceuticals prepared from polycyclic bases and cation exchange resins
GR61158B (en) N-tetrahydrofurfuryl-noroxymorphone,salts thereof by addition of acid,pharmaceutical mediums containing them and process for the preparation thereof
GB869149A (en) Liquid pharmaceutical compositions comprising compounds of ion exchange resins and therapeutic substances
GB982150A (en) Therapeutic resin complexes
US3108044A (en) Medicament of polystyrene anion exchange resin having a barbiturate adsorbed thereon
US3070503A (en) Pyrilamine resin absorbate with aspirin and/or ascorbic acid
Rogers et al. Depression of cerebral metabolism by stimulant doses of cocaine.
Kennon et al. Interaction Studies of Cationic Drugs with Anionic Polyelectrolytes I: Sodium Carboxymethylcellulose
US3342685A (en) Vitamin-cation exchange resin therapy and method of eliminating drug odor
CN101422611A (en) Compound preparation and preparation method thereof
US3035979A (en) Pharmaceutical composition containing a resin-narcotic compound and a resinantihistamine compound
GB1440582A (en) Anion exchange resins
GB1378007A (en) Ion-exchange resin and ion-separation method using the same
GB934285A (en) Pharmaceutical preparation comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon